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Abstract 
Spreading depolarizations (SDs) are profound disruptions of cellular homeostasis that slowly propagate through gray 
matter and present an extraordinary metabolic challenge to brain tissue. Recent work has shown that SDs occur com-
monly in human patients in the neurointensive care setting and have established a compelling case for their impor-
tance in the pathophysiology of acute brain injury. The International Conference on Spreading Depolarizations (iCSD) 
held in Boca Raton, Florida, in September of 2018 included a discussion session focused on the question of “Which 
SDs are deleterious to brain tissue?” iCSD is attended by investigators studying various animal species including 
invertebrates, in vivo and in vitro preparations, diseases of acute brain injury and migraine, computational modeling, 
and clinical brain injury, among other topics. The discussion included general agreement on many key issues, but 
also revealed divergent views on some topics that are relevant to the design of clinical interventions targeting SDs. A 
draft summary of viewpoints offered was then written by a multidisciplinary writing group of iCSD members, based 
on a transcript of the session. Feedback of all discussants was then formally collated, reviewed and incorporated into 
the final document. It is hoped that this report will stimulate collection of data that are needed to develop a more 
nuanced understanding of SD in different pathophysiological states, as the field continues to move toward effective 
clinical interventions.
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Introduction
First described in the 1940s, spreading depolariza-
tions (SDs) are profound disruptions of homeostasis 
that slowly propagate through gray matter and induce 
suppression of cortical activity (termed “spreading 
depression”). For decades after their first description, SDs 
were generally regarded as a research curiosity and often 
were exploited merely as a laboratory tool to study brain 
function. However, work of an international research 
consortium (Co-Operative Studies on Brain Injury Depo-
larizations, COSBID.org) has conclusively shown that 
SDs occur commonly in human patients and established 
a compelling case for their importance in the patho-
physiology of acute brain injury. Since the first COSBID 
meeting in 2003, its members have generally focused 
on recording SDs in the setting of neurocritical care, 
and testing the idea that SDs contribute to injury. Over 
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the last 15  years, the SD field, including both clinical 
and preclinical research, has grown quite dramatically, 
largely due to the translational success of this work and 
growing recognition of the potential therapeutic impor-
tance of SDs in stroke, traumatic brain injury, and other 
disorders. As the field has grown, the annual COSBID 
meeting has evolved into the International Conference 
on Spreading Depolarizations (iCSD), an open meeting 
which welcomes and discusses a broad range of perspec-
tives that bear on SD mechanisms and consequences. 
iCSD is attended by investigators studying various ani-
mal species including invertebrates, in vivo and in vitro 
preparations, diseases of acute brain injury and migraine, 
computational modeling, and clinical brain injury, among 
other topics. This article is a report of a formal discus-
sion session at the second iCSD meeting, held at Boca 
Raton, Florida, September 22–24, 2018, with participants 
from 14 countries (http://www.cosbi d.org/wp-conte nt/
uploa ds/2018/10/iCSD2 018-progr am_FINAL .pdf ). The 
goal of the session was to discuss the question of “Which 
SDs are deleterious to brain tissue?” and gain a sense of 
what factors may render some SDs more injurious than 
others. This is not intended to be a consensus statement, 
nor is it intended to provide a comprehensive review of 
the relevant literature. In contrast, the transcript from 
the session was used as a framework to capture the main 
opinions that were expressed. It is hoped that this report 
may be useful to stimulate collection of data that are 
needed to resolve key issues, as we continue to develop 
a more nuanced understanding of SD in different patho-
physiological states.
Harmful Effects of SD
Multiple discussants emphasized that there is strong 
data, accumulated over decades, showing that SDs can 
be harmful to brain. Recent reviews were referenced, 
summarizing the case that SDs can cause the develop-
ment and expansion of ischemic lesions, including both 
animal and clinical studies co-authored by some of the 
attendees. Multiple mechanisms have been described 
to explain damage caused by SD in this context, and it 
was noted that consistent supporting data can be found 
across the spectrum of studies from reduced prepa-
rations (brain slices) and animal models through to 
clinical recordings. The progression of deterioration is 
stepwise with SDs in animals and patients and can be 
attributed to the SD itself, rather than other physiologic 
variables. Much of the causative evidence is derived 
from monitoring several variables simultaneously. 
These data show that pathologic changes in major tissue 
variables, such as reduced cerebral blood flow or intra-
cellular  Ca2+ loading, develop in a spreading manner 
as a consequence of SD. The major mechanisms by 
which SDs are thought to cause cellular injury include 
ATP depletion, excitotoxicity, and spreading ischemia. 
Spreading ischemia is an SD-induced, local decrease 
in cerebral blood flow that is observed in both animals 
and patients and prolongs the electrophysiologic, depo-
larized state. It was pointed out these sequences have 
been demonstrated in many patients, and it was argued 
that deleterious effects of SD in causing tissue death 
have been nearly proven clinically.
Additional comments supporting these points 
focused on the energy challenge presented by SD. SD 
is an unusual phenomenon, in that membrane poten-
tial is almost completely dissipated for tens of seconds 
to minutes and the energy required to repolarize is 
extreme. In addition to the massive amount of energy 
used to reestablish ionic gradients after SD, there are 
dramatic structural changes that must also be reversed. 
These changes include cellular swelling, fragmenta-
tion of endoplasmic reticulum, disruption of dendritic 
spines and other distortions have been well described 
during SD. Despite this challenge, mature neurons in 
healthy brain are able to recover relatively quickly and 
regain function, at least from SDs occurring in isola-
tion. Yet on-line microdialysis recordings from patients, 
obtained with either rapid-sampling or continuous on-
line microdialysis, SD results in sharp decreases in local 
brain glucose levels. Since this was observed regardless 
of the initial health of the tissue, it was interpreted that 
SD invariably moves the brain toward a more meta-
bolically compromised state. While there are some tis-
sue metabolic reserves (e.g., astrocytic glycogen) that 
mitigate the risk of complete failure, repetitive SDs are 
expected to progressively drive glucose to detrimental 
levels. From this perspective, it was argued that SDs are 
always detrimental to tissue, at least from a metabolic 
standpoint. Temporal clusters of SDs were considered 
particularly harmful, as metabolic reserves cannot be 
re-established between each event.
A note of caution was raised that, in some circum-
stances, evidence for the relationship between SD and 
injury progression is strictly correlative rather than 
causative. A further caution was that the experimental 
manipulations (e.g., potassium application) that inves-
tigators use to induce SD might be sufficient to increase 
infarct volumes, without additional detrimental effects 
of the SDs themselves. This can lead to erroneous con-
clusions about the effects of SDs. In support of this 
view, a paper presented at this meeting found that SDs 
induced by optogenetic stimulation, which presumably 
has no impact by itself, had no effect on infarct vol-
umes. Thus, the role of the stimulus should be carefully 
controlled and considered in conducting and interpret-
ing experimental SD studies.
Continuum of susceptibility to damaging effects 
of SD
The discussion moved quickly to the question of “what 
determines the conditions under which SDs are harm-
ful?” Much progress has been made on this point, both 
in the laboratory and in clinic. The idea of a continuum of 
vulnerability to SD, depending on the baseline metabolic 
capacity of tissue (e.g., due to distance from focal lesion, 
or global differences in perfusion between patients), has 
been articulated in recent reviews. Animal studies have 
provided detailed information about the regional heter-
ogeneity of tissue surrounding a focal injury, and it was 
emphasized that stark differences in consequence can 
be seen even over quite small distances, such as loca-
tions relative to the nearest arteriole. The clinical impli-
cations of this general point were illustrated with two 
case reports describing very different outcomes associ-
ated with SD. In the first, a middle-aged man had more 
than 100 SDs over the initial days after surgical removal 
of a hematoma, yet had an excellent outcome with no 
deficits. In contrast, another patient deteriorated dramat-
ically after only 4–5 SDs, with a transition of the electro-
corticogram (ECoG) from healthy to flat during the SD 
cluster. Discussion focused on the differences in perfu-
sion and characteristics of the SDs in the two different 
cases. In the first case, good perfusion was maintained 
throughout the recording period, and SDs were of short 
duration, conditions that together meant that metabolite 
resupply could keep up with the challenge of the scores 
of events. In contrast, much longer-lasting SDs were seen 
in the context of damage in the second case. Prolonged 
SD events are observed if blood flow is substantially 
decreased, and tissue dies when they are prolonged for 
extended periods (e.g., ~ 20 min).
SDs that occur during migraine were discussed as a 
related example of non-damaging SDs. SD is thought 
to underlie the propagation of visual aura, and, unlike 
brain injury, events are initiated by intense activation 
of a region of healthy visual cortex rather than by focal 
ischemia or trauma. Discussants noted that despite a 
lifetime of repetitive SDs, there is no reported long-
term deficit to visual cortex or its function. The acute 
visual disturbances during SD (scintillation due to 
the advancing SD wave front, and scotoma due to the 
brief suppression of cortical activity in the wake of SD) 
can be resolved in this tissue that is otherwise healthy 
prior to SD onset. The comparison with seizures was 
also raised as a good way of thinking about the contin-
uum of SDs effects. Although the acute effects of sei-
zures are magnitudes smaller than SDs, they can also 
have disparate effects on tissue metabolism and fate, 
depending on the state of the tissue involved. Related 
discussion focused on the need to build on prior pub-
lished work examining the close relationship between 
seizures and SD, and the conditions under which one 
may trigger the other.
There was agreement that the character of an SD 
changes depending on where it occurs in the brain, and 
multiple discussants emphasized the severe technical 
limitation in the ability to detect where SDs originate 
and propagate. Current clinical recording methods rely 
on use of a single 1 × 6 subdural electrode strip which 
covers ~ 5 cm of brain. This extensive spatial sampling 
was considered a major advantage since it allows SD 
recordings, in an ideal case, from an injury focus into 
more normal brain. SDs with long durations character-
istic of an evolving lesion are often recorded. However, 
it was pointed out that recordings of SDs with only 
short durations do not necessarily indicate that the SDs 
are less injurious, but only that they are less injurious 
at the recording sites. In injured brain (e.g., in stroke or 
trauma), it could be assumed that SD usually has dam-
aging effects where it is initiated in vulnerable ischemic 
or penumbral regions, which may or may not be cap-
tured in the recordings, depending on the location of 
the electrode strip. One opinion therefore is that detec-
tion of any SD suggests that there is likely SD-induced 
damage occurring in vulnerable regions near the devel-
oping lesion focus, even if it has a short duration at 
recording sites. This viewpoint has important implica-
tions for the design of clinical intervention strategies, 
but needs to be fully reconciled with the prior com-
ment that some patients can have scores of SDs and still 
have excellent outcomes.
A case example reported at the iCSD meeting illus-
trated the dilemma of different SD effects depending 
on brain location. The recordings of this patient dem-
onstrated dramatically different SD durations, and dif-
ferent sensitivity to pharmacological inhibition, at two 
different recording locations. There was consensus that 
it would be helpful to have methods to observe SDs 
over larger regions, especially surrounding focal brain 
injuries, and the question was raised as to which other 
types of monitoring might be most helpful. Examples 
considered included clinical monitoring of inflamma-
tory status, use of multiple subdural ECoG strips, scalp 
electroencephalogram, depth electrodes, and markers 
of metabolic status. Brain imaging methods, including 
regional blood flow assessments, were also considered 
as useful clinical adjuncts to continuous focal monitor-
ing. The size of a region of ischemia is likely important 
in determining the functional impact of injury-induced 
SDs. Follow-up discussion on this point is included 
in the companion report (“What should a clinician 
do when spreading depolarizations are observed in a 
patient?”), as it focused on the sensitivity of clinical 
outcome measures.
Potential Beneficial Effects of SD
As noted above, there is a rich history of preclinical SD 
research spanning the decades from the original dis-
covery of SD in rabbits in the 1940s. This work includes 
brain slices, small animal models, and a wide array of 
biochemical, electrophysiological, and imaging meth-
ods. While a great number of these studies are motivated 
by an interest in detrimental effects of SD, the literature 
also includes diverse reports of other SD effects, includ-
ing some that may confer benefit. Examples noted dur-
ing the session included synaptic strengthening induced 
by SD, increases in neurotrophic factors, neuroprotec-
tive preconditioning, and neurogenesis. One study pre-
sented at this meeting suggested that SDs limit expansion 
of intracerebral hemorrhage in the mouse. The strong 
hyperemic response to SD that can be observed in 
healthy tissues could also have positive effects, perhaps 
relevant to tissues outside vulnerable penumbral zones. 
It may not be surprising that an event as extreme as SD 
can modify quite a range of processes in complex brain 
tissue, but the discussion addressed the issue of whether 
some of these actions of SD are beneficial in the context 
of a brain-injured patient. This theoretical possibility is 
sometimes raised as a caution when considering thera-
peutic interventions to block SD in injured brain. Multi-
ple discussants emphasized that it is very reasonable for 
a phenomenon like SD to have either beneficial or det-
rimental effects, depending on the tissue circumstances. 
The process of inflammation was cited as a relevant anal-
ogy, where in some cases inflammatory processes can be 
essential for disease mitigation, but in others can contrib-
ute to cellular injury. Likewise, hyperthermia was noted 
as an evolutionarily conserved process that provides ben-
efit by fighting infection, yet is aggressively counteracted 
therapeutically in the intensive care unit because of the 
clear detrimental effects in that particular context.
Theoretical considerations aside, there was debate in 
the group about the existence of actual data supporting 
the beneficial effects of SD in the context of focal injury. 
At the present time, there appears to be little or no direct 
evidence that SD has meaningful beneficial effects in 
patients, in contrast to the strong accumulated evidence 
for contribution to injury. Furthermore, it was noted that 
any evidence for benefit would have to be dramatic to 
outweigh the potential therapeutic gains of treating and 
preventing SDs. Some discussants argued that this con-
clusion could be very biased by the fact that our field has 
focused mainly on the injury aspects of SD. Thus, we have 
to acknowledge the issue of selection bias in all of our 
discussions. It was further noted that we may be biased 
by the use of invasive clinical monitoring that targets the 
most injurious SDs near a lesion focus in the context of 
severe injury. The suggestion was made that without the 
ability to detect SD non-invasively, we may be missing a 
great deal, including events that are non-injurious and 
yet have other important effects, perhaps in non-dam-
aged brain regions or in patients with less severe inju-
ries. Again it was emphasized that non-invasive methods 
to study SD in non-injured animals and human subjects 
would help advance this discussion beyond provocative 
conjecture.
In response, a challenge was laid out for our field to 
rigorously test the hypothesis that there are meaningful 
effects of SD that improve outcome from injury, since this 
hypothesis has not been directly tested in animal models. 
For example, the notion that SD enables adaptive neu-
roplasticity that facilitates functional recovery could be 
tested by mapping reorganization of neuronal receptive 
fields in somatosensory cortex after focal ischemia, with 
versus without suppression of acute SDs by N-Methyl-
D-aspartic acid receptor antagonists. The effect of SD to 
induce neurogenesis could also be examined in the con-
text of injury, rather than only in healthy control animals. 
Similarly, it was suggested that preconditioning effects 
should be examined in relation to SDs that occur post-
injury, to determine whether they mitigate against dam-
age from a subsequent ischemic insult, such as occurs 
with delayed cerebral ischemia after aneurysmal suba-
rachnoid hemorrhage. Such studies should include meas-
ures of behavioral outcome to examine functional benefit 
to recovering animals.
Broader Biological Implications
There was robust and contentious discussion on the 
question of whether SDs are an evolutionarily conserved 
mechanism. This was inspired, in part, from reports at 
iCSD meetings about SDs in invertebrate animals. In 
locusts, SDs occur in the central nervous system after 
water immersion and induce a functional block that 
improves animal survival. These interesting observations 
are being extended with behavioral studies in Drosophila 
(fruit fly). A similar result in mammals was presented at 
this meeting, showing that earlier onset of SD after car-
diac arrest in the rat is associated with better neurologi-
cal outcome. In a purely speculative discussion, potential 
beneficial effects of SD were then considered from a 
human evolutionary perspective. It was suggested that, 
in the context of brain injury, adverse effects of SD could 
increase a group’s survivability by further incapacitating 
a weakened, injured member (i.e., analogous to “thinning 
the herd”). An alternate suggestion was that SD could 
provide an adaptive advantage following a traumatic 
brain injury by causing a quiet (rather than seizing) state 
of physical incapacitation (i.e. loss of consciousness), 
thus reducing the risk of detection by predators, if there 
is widespread, rapid depolarization. Others objected that 
there is no evidence of such widespread depolarization 
onset and that SD travels just as slowly in the large gyren-
cephalic human brain as it does in locust ganglia. It was 
further cautioned that the field should not fall victim to 
Stephen Jay Gould’s “Panglossian paradigm,” the assump-
tion that every feature or process in biology was selected 
or ideally adapted for a specific purpose. Rather, suscep-
tibility to SD may be an unavoidable consequence of the 
close packing of neurons and, rather than conferring any 
evolutionary advantage, may be an inherent vulnerability 
of nervous systems of sufficient complexity and organiza-
tion. However, these ideas are challenged by the fact that 
some nervous tissue, such as nuclei of the lower brain 
and mammalian autonomic ganglia, are resistant to SD 
despite neuronal packing density similar to SD-vulnera-
ble tissue. Discussion of these broader biological implica-
tions of SD has expanded at recent iCSD meetings, and a 
review manuscript is currently being prepared.
Conclusions
There was general agreement that some or many SDs are 
harmful, particularly under tissue conditions of meta-
bolic compromise, and some took the view that all SDs 
should be considered detrimental in the context of acute 
brain injury. On the other hand, it was generally accepted 
that SDs can be benign in certain contexts such as healthy 
brain or migraine aura, and some have emphasized the 
possibility even of beneficial effects. The distinction 
between benign and beneficial emerged as an important 
one, since the presence of benign effects for some SDs 
or some brain regions would not contraindicate inter-
ventional therapies to block harmful SDs. Beneficial or 
protective effects of SD, on the other hand, might raise 
serious caution against such approach. This considera-
tion suggested the need for studies that directly address 
the hypothesis of beneficial effects in the context of brain 
injury, which to date have not been conducted. The need 
to define endpoints that would demonstrate benefit was 
emphasized. Given the importance of energy depletion 
in rendering SDs more deleterious, it was also suggested 
that future therapeutic efforts should consider improving 
tissue perfusion, rather than solely focusing on SD block-
ade. Such approaches would be particularly attractive if 
SD has beneficial effects or if treatments to block SDs 
carry worrisome side effects. Finally, there was consensus 
that more studies are needed on the initial persistent SD 
after global insults, such as anoxic SD after cardiac arrest. 
Not only is cardiac arrest underrepresented in this field, 
but such studies would allow more direct comparison to 
insect studies and hence a better understanding of SD 
from an evolutionary perspective. Not the least, Leão’s 
original studies compared SD in normal brain and after 
global ischemia, and his results continue to serve as a 
benchmark for our understanding today.
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